Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.

By E. Akriviadis, Ravi Botla, W. Briggs, S. Han, T. Reynolds, O. Shakil. Gastroenterology, 2000

761 citations recorded by the source corpus.

Subfields: Hepatology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/990161f085ee3c0d5e83267d8cd9becee8f93e0b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. P. Ginés
2. B. Runyon
3. G. Garcia‐Tsao
4. Rajeshwar P. Mookerjee
5. P. Kamath

Citations in the corpus

• The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids (2007, methodology): “All patients with a DF 32 or encephalopathy at admission were treated by corticosteroids if they fulfilled the following criteria: (1) a history of alcoholism; (2) liver chemistry suggestive of AH; (3) the absence of uncontrolled infection or recent gastrointestinal hemorrhage ( 15 days); (4) transj”
• Management of adult patients with ascites due to cirrhosis (2004, background): “This drug has also been shown to prevent hepatorenal syndrome and improve survival in patients with severe alcoholic hepatitis.(175) Treatment.”
• Alcohol-induced oxidative stress. (2007, background): “In another study, Pentoxifylline (PTX), an inhibitor of TNFα and other cytokines, decreased the occurrence of hepatorenal syndrome in alcoholic hepatitis patients (Akriviadis et al., 2000).”
• Acute-on chronic liver failure. (2012, background): “The important pathophysiological role of inflammation in modulating renal dysfunction associated with ACLF is highlighted by the benefit of anti-inflammatory agents such as albumin, pentoxifylline and N-acetylcysteine, which decreased the risk of renal dysfunction in patients with alcoholic hepatiti”
• Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2020, neutral): “(183) Subsequent trials have failed to confirm this survival benefit, but have shown a reduction in the development of HRS in patients with AH who received pentoxifylline.”
• Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 (2013, background): “This drug has also been shown to prevent hepatorenal syndrome and improve survival in patients with severe alcoholic hepatitis.(175) Treatment.”